Observational studyJournal of translational medicine2026
Efficacy of very low calorie diet in the intervention of obesity and the changes in oral microbiota: a prospective cohort study.
Observational study in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVery Low Calorie Diet (VLCD) is a stringent caloric restriction regimen used in the short-term management of obese patients, which can effectively reduce body weight and blood glucose levels. This prospective study aimed to evaluate the short-term impacts of a VLCD on body composition, metabolic parameters, and oral microbiota in obese adults, exploring its therapeutic potential for metabolic dysfunction and inflammation-related comorbidities.
methodsThis prospective study was conducted on the basis of a cohort of overweight/obese individuals at Affiliated Hospital of Hubei University of Chinese Medicine. Patient eligibility for inclusion in this study was determined by the adoption of a complete short-term VLCD therapy following their entry into the cohort. The study aimed to explore the improvements in body composition, blood glucose, blood lipids, and inflammatory markers post-VLCD intervention, as well as the safety of the treatment. Additionally, it analyzed the changes in the microbiota of the upper gastrointestinal tract, specifically the oral coating. The study was concluded on December 31, 2023.
resultsIn the per-protocol cohort (n = 101), the VLCD intervention induced rapid, clinically meaningful reductions in body weight, body fat mass(BFM), body mass index (BMI), and visceral fat area(VFA). Skeletal muscle mass(SMM) decreased modestly. Metabolic parameters improved significantly, with decreases in fasting blood glucose (FBG), fasting insulin (FIns), and homeostasis model assessment of insulin resistance (HOMA-IR). Lipid profiles showed transient increases in low-density lipoprotein cholesterol (LDL-C) and total cholesterol (CHOL) at day 5, normalizing by two-week follow-up, alongside reduced triglycerides (TG). Systemic inflammation markers declined after resuming normal diet, including alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hs-CRP); uric acid (UA) peaked transiently during the VLCD before falling below baseline. Tongue-coating microbiota exhibited increased Shannon diversity and shifted community structure, with 12 reduced species associated with 19 systemic diseases.
conclusionsThe VLCD intervention shows significant short-term benefits in weight loss and body fat reduction. Furthermore, it shows potential for reducing the risk of chronic diseases by modulating systemic inflammation and altering the oral microbiome. Further studies are warranted to assess long-term efficacy and sustainability.
trial registrationChinese Clinical Trail Registry (No. ChiCTR2200063126, date of registration: 31 August 2022), https://www.chictr.org.cn/hvshowproject.html?id=188695&v=1.2 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.